We are live on
!
Find out more
SGH
Sivik Global Healthcare Portfolio holdings
AUM
$132M
1-Year Est. Return
24.1%
This Fund
S&P 500
This Quarter
Est. Return
+13.1%
1 Year Est. Return
+24.1%
3 Year Est. Return
+53.78%
5 Year Est. Return
+97.1%
10 Year Est. Return
+690.63%
AUM
$273M
AUM Growth
+$58.5M
(+27%)
Cap. Flow
+$33.4M
Cap. Flow
% of AUM
12.22%
Top 10 Holdings %
Top 10 Hldgs %
31.23%
Holding
76
New
17
Increased
24
Reduced
16
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$8.93M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$6.98M |
| 3 |
Gilead Sciences
GILD
|
+$5.99M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$4.38M |
| 5 |
Stryker
SYK
|
+$4.12M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$6.73M |
| 2 |
Zimmer Biomet
ZBH
|
+$4.88M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$4.21M |
| 4 |
Tenet Healthcare
THC
|
+$3.98M |
| 5 |
AstraZeneca
AZN
|
+$3.89M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.53% |
| 2 | Financials | 2.5% |
| 3 | Energy | 1.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CLVS
51
DELISTED
Clovis Oncology, Inc.
CLVS
| $1.87M | 0.69% |
20,000
| – | – |
|
|
KITE
52
DELISTED
Kite Pharma, Inc.
KITE
| $1.87M | 0.68% |
18,000
| – | – |
|
|
DPLO
53
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
| $1.78M | 0.65% |
120,000
+19,000
| +19% | +$317K |
|
54
Puma Biotechnology
PBYI
$451M
| $1.75M | 0.64% |
20,000
-10,000
| -33% | -$559K |
|
55
Illumina
ILMN
$28.9B
| $1.74M | 0.64% |
10,280
| – | – |
|
|
PTLA
56
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $1.69M | 0.62% |
+30,000
| New | +$1.2M |
|
|
LOXO
57
DELISTED
Loxo Oncology, Inc
LOXO
| $1.64M | 0.6% |
+20,500
| New | +$1.14M |
|
|
SAGE
58
DELISTED
Sage Therapeutics
SAGE
| $1.59M | 0.58% |
20,000
| – | – |
|
|
BCR
59
DELISTED
CR Bard Inc.
BCR
| $1.58M | 0.58% |
5,000
-5,000
| -50% | -$1.48M |
|
|
BLUE
60
DELISTED
bluebird bio
BLUE
| $1.58M | 0.58% |
1,158
+85
| +8% | +$103K |
|
61
Acadia Pharmaceuticals
ACAD
$5.07B
| $1.53M | 0.56% |
55,000
-10,000
| -15% | -$298K |
|
|
KND
62
DELISTED
Kindred Healthcare
KND
| $1.46M | 0.53% |
125,000
+27,785
| +29% | +$274K |
|
|
SGEN
63
DELISTED
Seagen Inc. Common Stock
SGEN
| $1.29M | 0.47% |
25,000
+10,000
| +67% | +$636K |
|
64
Neurocrine Biosciences
NBIX
$16.7B
| $920K | 0.34% |
20,000
-5,000
| -20% | -$243K |
|
|
65
AstraZeneca
AZN
$251B
| – | – |
-62,500
| Closed | -$3.89M |
|
|
66
Bristol-Myers Squibb
BMY
$133B
| – | – |
-77,400
| Closed | -$4.21M |
|
|
67
Eli Lilly
LLY
$1.08T
| – | – |
-80,000
| Closed | -$6.73M |
|
68
ResMed
RMD
$31.6B
| – | – |
-21,200
| Closed | -$1.53M |
|
69
Teva Pharmaceuticals
TEVA
$41.2B
| – | – |
-50,000
| Closed | -$1.6M |
|
|
70
Tenet Healthcare
THC
$21.1B
| – | – |
-225,000
| Closed | -$3.98M |
|
71
Viatris
VTRS
$18.8B
| – | – |
-60,000
| Closed | -$2.34M |
|
|
72
Zimmer Biomet
ZBH
$18.4B
| – | – |
-41,200
| Closed | -$4.88M |
|
|
PRXL
73
DELISTED
Parexel International Corp
PRXL
| – | – |
-35,000
| Closed | -$2.21M |
|
Similar funds
AFP
TCPW
GCM
PCGDR
ACM
A
SPWM
EWP
Sivik Global Healthcare's Q2 2017 Portfolio in Review
As of Q2 2017, Sivik Global Healthcare held 76 positions worth $273M, up 27% from $215M the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Sivik Global Healthcare deployed $33.4M of net new capital in Q2 2017, opening 17 new positions and adding to 24 existing holdings. Its largest new stake was Johnson & Johnson: 70,000 shares worth $9.26M.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 88% a quarter earlier, followed by Financials and Energy.
On the sell side, the largest reduction was Wellcare Health Plans, Inc., an estimated $3.31M trimmed.
- Sivik Global Healthcare's largest Q2 2017 buy was Johnson & Johnson: 70,000 shares worth $9.26M.
- Sivik Global Healthcare added most to Alexion Pharmaceuticals in Q2 2017, an estimated $6.98M increase.
- Sivik Global Healthcare's biggest Q2 2017 reduction was Wellcare Health Plans, Inc., cutting an estimated $3.31M.
- Sivik Global Healthcare fully exited Eli Lilly in Q2 2017, selling an estimated $6.73M.
- Sivik Global Healthcare's ten largest holdings make up 31% of its $273M portfolio in Q2 2017.
- Sivik Global Healthcare opened 17 new positions and closed 9 in Q2 2017.
- Sivik Global Healthcare's portfolio value rose 27% quarter-over-quarter to $273M.
Based on Sivik Global Healthcare's 13F filing for Q2 2017, filed 11 Aug 2017.